Loverin

Quick links to important sections

Loverin

Method of action: Analgesic, Antispasmodic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loverin

Property Description
Active ingredient Dicycloverine (Dicyclomine)
Form Tablet, Capsule, Oral Solution, Injectable Solution
Pharmacological class Antispasmodic, Anticholinergic agent
Common use Relief of smooth muscle spasms and colicky pain
Origin Synthetic

What is Loverin and its Core Classification?

Loverin is a synthetic, single-ingredient prescription medication defined by the internationally recognized nonproprietary name (INN) of its active component, Dicycloverine (also known as Dicyclomine). It is formally classified as an anticholinergic agent and, more specifically, as an antispasmodic agent. The medication's classification is clinically recognized for targeting and relaxing the smooth muscle tissue of the intestinal walls, distinguishing its action from traditional central analgesics. This core identity establishes that the drug is designed to address muscle overactivity in the digestive system.

Dicycloverine's pharmacological properties include the reduction of hypermotility and spasms within the gastrointestinal tract due to its anticholinergic nature. Its pharmacological profile indicates the medicine’s core strength lies in its ability to directly calm an overly active digestive system, which is a key focus for individuals experiencing functional bowel discomfort.


Composition, Available Forms, and General Purpose

The medication is chemically composed of Dicycloverine hydrochloride as the essential therapeutic substance. Dicycloverine is available in a variety of pharmaceutical preparations, which include solid forms such as the tablet and capsule, and liquid preparations like the oral solution and an injectable solution for intramuscular administration. This range of forms allows flexibility in administration, particularly for patients who may have difficulty swallowing solid medication. The general purpose of Dicycloverine is the reduction of spasms and cramping that occur within the gastrointestinal tract, a typical use being the alleviation of discomfort during periods of colicky abdominal pain. By relaxing the smooth muscles of the gut wall, the drug acts to decrease excessive intestinal motility and the associated colicky pain often seen in functional bowel disorders.

What side effects are possible with Loverin?

Possible Side Effects and Safety Information

The safety profile of Loverin (Dicycloverine) is defined by its core anticholinergic activity, which leads to a range of officially documented adverse reactions classified by frequency and affected organ system. This information is derived from official government regulatory sources.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their rate of occurrence in clinical trials:

  • Very Common (reported in ge 10% of patients): Dry mouth (xerostomia), dizziness, and blurred vision [FDA Label].
  • Common (reported in 1% to 10% of patients): Nausea, light-headedness, drowsiness (somnolence), asthenia (weakness), and nervousness [FDA Label].

System-Organ-Class Safety Groups

The drug's anticholinergic effects manifest across several systems, including:

  • Nervous System Disorders: Leading to effects such as sedation, headache, and nervousness.
  • Eye Disorders: Including mydriasis (dilated pupils) and loss of visual accommodation.
  • Cardiac Disorders: Palpitations and tachyarrhythmia are documented reactions [DailyMed].

Serious Adverse Reactions and Safety Constraints

Certain serious reactions and limitations are explicitly noted in regulatory documents:

  • Serious CNS Effects: Confusion, disorientation, hallucinations, and psychosis have been reported, particularly in older adults [DailyMed]. These symptoms are documented to usually resolve within 12 to 24 hours after discontinuing the medicine.
  • Infant Contraindication: Loverin is contraindicated in infants under six months of age due to reports of serious respiratory and CNS symptoms, including apnea and respiratory collapse [DailyMed].
  • High-Risk Constraints: The medicine must not be used (is contraindicated) in patients with obstructive diseases of the gastrointestinal or urinary tracts, closed-angle glaucoma, and myasthenia gravis, as its pharmacological action may aggravate these conditions [DailyMed].

Overdose and Emergency Response

The official regulatory profile for Dicycloverine (Loverin) overdose is defined by the severe escalation of its anticholinergic properties. Documented clinical manifestations of overdose include blurred vision, dilated pupils, hot and dry skin, dry mouth, and difficulty swallowing. Central Nervous System (CNS) stimulation is evident through effects such as confusion, disorientation, and hallucinations, which are listed in the official prescribing information.

A severe overdose is classified as life-threatening and may involve outcomes such as coma and profound muscular weakness progressing to paralysis, which is described in regulatory documents as a curare-like action. The regulatory profile specifically notes that infants have a heightened risk for serious adverse events, including officially documented seizures, apnea, and respiratory collapse.

Mandatory actions require seeking immediate medical attention. Individuals must immediately call emergency services if the affected person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Procedural treatment measures described in the regulatory context include gastric lavage and the administration of activated charcoal. Furthermore, an appropriate parenteral cholinergic agent is officially acknowledged as a potential antidote for use in clinical management.

Therapeutic Uses of Loverin

Quick Facts

  • Supports Management of: Irritable Bowel Syndrome (IBS)
  • Aids in Addressing: Gastrointestinal (GIT) spasms
  • May Help Alleviate: Colicky abdominal pain

Loverin is a prescription medication indicated for the therapeutic management of functional bowel disorders, primarily Irritable Bowel Syndrome (IBS). Its primary application is to help relieve the discomfort and address the symptoms associated with gastrointestinal (GIT) spasms.

This medication is used to support individuals experiencing conditions such as abdominal colic, colicky abdominal pain, and spasms of the digestive tract. It may also provide relief for symptoms of infantile colic in patients over six months of age, and is sometimes employed to support the care of urinary incontinence that is secondary to unstable detrusor muscle. Loverin serves as a beneficial option for those who require pharmaceutical support to maintain the stability of the gastrointestinal system.

Eligibility and Restrictions for Use

Loverin (Dicycloverine) has a strictly defined population eligibility profile based on official regulatory documentation. The medicine is absolutely contraindicated in several specific patient groups. These prohibitions include infants less than six months of age and nursing mothers.

Contraindicated medical conditions include obstructive diseases of the gastrointestinal tract and urinary tract (obstructive uropathy), glaucoma, myasthenia gravis, severe ulcerative colitis (due to the risk of toxic megacolon), reflux esophagitis, and unstable cardiovascular status in acute hemorrhage.

Use is generally permitted for adults and pediatric patients six months of age and older, though safety and effectiveness in children have not been established in all regulatory contexts.

The official labeling requires caution when the medicine is administered to individuals with hepatic or renal impairment, prostatic enlargement, autonomic neuropathy, and cardiovascular conditions such as coronary heart disease or cardiac tachyarrhythmia. Older adults should also use the medicine with caution. Use during pregnancy is permitted only if clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Loverin is defined by its metabolism and its potential for pharmacodynamic synergy with other agents, as documented in official regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with strong CYP3A4 inhibitors is explicitly contraindicated. This class includes certain antifungals (e.g., itraconazole, ketoconazole), macrolide antibiotics (e.g., clarithromycin), and HIV protease inhibitors, as these agents significantly increase Loverin’s systemic exposure. The use of Gemfibrozil and Cyclosporine is also generally avoided due to the high risk of significantly increased drug levels and related toxicity.

Exposure and Dose Constraints

The drug is a substrate for the CYP3A4 enzyme. This necessitates specific dose restrictions when co-administered with moderate CYP3A4 inhibitors such as Amiodarone, Diltiazem, or Verapamil, where a maximum daily dose of Loverin must not be exceeded. In cases where strong inhibitors are required short-term, regulatory guidelines mandate the temporary suspension of Loverin treatment. Furthermore, the consumption of grapefruit juice is not recommended as it also inhibits CYP3A4, resulting in clinically significant increases in drug plasma concentration.

Pharmacodynamic and Population Notes

The risk of muscle-related toxicity is increased when Loverin is combined with other lipid-modifying agents, such as Niacin (ge 1 g/ day), representing a pharmacodynamic interaction. Regulatory documents also note that exposure may be approximately two-fold higher in patients with severe renal impairment ( CrCl 10 –30 mL/ min), which elevates the potential for drug interactions in this population.

Mechanism of Action

Loverin (Dicycloverine) utilizes a dual mechanism that addresses two distinct components of smooth muscle function: the nervous system's signal and the muscle cell's intrinsic excitability. Its classification as an anticholinergic agent means it engages the parasympathetic nervous system, while its musculotropic properties provide a direct modulation of muscle fiber excitability.

The drug's core action is the competitive antagonism of muscarinic acetylcholine receptors ( mAChRs), particularly the M3 subtype, which mediates smooth muscle contraction in the gut. By occupying these receptors, Dicycloverine prevents the excitatory signal from Acetylcholine ( ACh) from binding and initiating the cascade that leads to shortening of the muscle fibers. This targeted suppression of the cholinergic pathway results in a decrease in the frequency and coordination of intestinal contractility.

Independent of receptor antagonism, Dicycloverine also performs a direct, non-competitive inhibition of the smooth muscle cell. This musculotropic action stabilizes the cell membrane and decreases its responsiveness to local pro-contractile mediators, such as histamine and bradykinin. The combined effect of nervous signal blockade and direct muscle stabilization results in a reduction of intestinal muscle tone and contractility.

Dosage and Administration Information

The administration of Dicycloverine (Loverin) is available across two routes: the oral route for maintenance and the intramuscular (IM) route reserved for short-term situations. The injectable solution must be administered via the IM route only; intravenous (IV) injection is not for use.

Oral therapy for adults typically begins with an initial dose of 20 mg four times a day (QID). This oral dosage may be increased to a maximum of 40 mg QID (total 160 mg daily) after a one-week trial, provided the dose is tolerated. For the injectable solution, the dose ranges from 10 mg to 20 mg QID, with a total daily dose not to exceed 80 mg. The IM route is intended to be used for a maximum duration of one to two days, after which transition to oral therapy occurs.

Specific parameters apply to the intake of the medication. Oral Dicycloverine may be taken with or without food, but is not taken simultaneously with antacids; a separation of two hours is required. For the oral solution, the preparation is diluted with an equal volume of water just prior to administration. Use is typically discontinued if sufficient results are not established within two weeks or if side effects prevent achieving a dose of at least 80 mg daily. The medication is contraindicated in infants younger than six months of age, and older adult patients typically start at the lower end of the established dose range.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Loverin (Dicycloverine)

This section provides a summary of the published research and clinical trials that form the regulatory and scientific basis for Dicycloverine. The information focuses only on the study designs, the outcomes that were measured, and the overall assessment of the evidence by authoritative bodies, without giving any clinical advice or making claims about guaranteed personal results. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Evidence for Use in Irritable Bowel Syndrome (IBS)

The research examining Dicycloverine for Irritable Bowel Syndrome (IBS)—a condition characterized by fluctuating or episodic manifestations—has primarily involved short-term Randomized Controlled Trials (RCTs). These studies typically included adult patients used in research exploring how symptoms change over time over a period of a few weeks.

What was studied: The studies mainly examined outcomes related to physical discomfort, such as changes in abdominal pain, abdominal tenderness, and the patient's overall global assessment of their condition. These patient-reported outcomes were measured to understand patterns observed in the studies related to symptoms during the study period.

What the studies reported: One key controlled trial reported that a larger proportion of patients described a greater change in overall global assessment scores compared to those who received a placebo over two weeks. However, scientific reviews often rate the quality of this specific evidence as very low, due to the limited number of studies and the age of the key research.

What remains uncertain: The primary research for Dicycloverine is considered dated, with a lack of contemporary, high-quality, long-term studies. Consequently, long-term effects are not fully established, as follow-up durations were limited to short intervals, such as two to eight weeks. There is limited information for long-term outcomes or the durability of symptom response with extended use of the medicine.


The Current Landscape and Evidence Gaps

A consistent finding across regulatory and systematic reviews is that the evidence quality varies across studies and the certainty remains low. Research has highlighted a need for more contemporary, methodologically rigorous clinical trials to further contextualize the existing evidence for Dicycloverine. The current research helps contextualize how patients reported their experience in the studies that were conducted, but the overall evidence landscape is characterized by older trials and modest sample sizes.

Key Studies & References

  1. Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride) - The pivotal 1981 RCT
  2. Dicyclomine for Gastrointestinal Conditions: A Review of the Clinical Effectiveness, Safety, and Guidelines (2015 CADTH Review)
  3. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines
  4. A REVIEW OF COCHRANE SYSTEMATIC REVIEWS INTERVENTIONS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME

Frequently Asked Questions (FAQ)

Common questions about Loverin (FAQ)


Q: How quickly do the effects of Loverin usually start to show?

Official documents state that Dicycloverine is absorbed quickly after taking it orally. Peak concentrations in the blood, which indicate when the medicine is working fastest, are typically reached within about 1 to 1.5 hours.


Q: What are the most commonly reported mild side effects of Loverin?

According to official product information, the most common mild side effects reported in studies include dry mouth, blurred vision, dizziness, nausea, drowsiness, and headache. Regulatory sources list these as frequent adverse reactions.


Q: What kind of warnings or precautions are included in the official Loverin documents?

Warnings in official documents cover several areas. These include potential effects on the Central Nervous System (CNS), such as confusion or drowsiness, and the risk of heat prostration because the drug can decrease sweating. Precautions are also noted for patients with specific existing heart or gastrointestinal conditions.


Q: Can women who are pregnant or breastfeeding use Loverin?

Regulatory documents state that Dicycloverine is categorized as Pregnancy Category B. However, the drug is contraindicated (strictly forbidden) in nursing mothers because it is excreted into human milk and may potentially cause adverse effects in the nursing infant.


Q: What if I have kidney or liver problems—can I still use Loverin?

Official information advises that this medication should be used with caution in patients with known hepatic (liver) or renal (kidney) disease. Regulatory caution notes that use in these conditions may require special monitoring due to how the drug is processed and eliminated by the body.


Q: How does alcohol consumption affect the safety of Loverin?

Official warnings state that consuming alcohol should be avoided while using this medication. Alcohol may increase the specific side effect of drowsiness or sedation that is associated with Dicycloverine.


Q: Will Loverin affect my ability to drive or operate machinery?

Dicycloverine may cause side effects like blurred vision or drowsiness. The labeling includes a statement that activities requiring mental alertness, such as driving a motor vehicle or operating machinery, should be avoided if these effects occur.


Q: Does Loverin affect blood pressure readings?

Official documents advise that the medication should be used with caution in patients with hypertension (high blood pressure) and other heart conditions. Official documents note that the drug may potentially increase heart rate, which is a consideration during its use.


Q: Is Loverin a habit-forming or controlled substance?

Dicycloverine is generally not classified as a controlled substance under federal law. However, abuse or dependence related to its anticholinergic effects has been reported in rare instances, and its use remains subject to prescription monitoring.


Q: Are there any long-term effects of taking Loverin?

Regulatory documents state that there are no known human data regarding the long-term potential for cancer-causing effects (carcinogenicity) or changes to genetic material (mutagenicity). Official safety data is primarily based on studies lasting up to two weeks.


Q: Is it possible to be allergic to an ingredient in Loverin?

Yes, regulatory documents list hypersensitivity (severe allergic reaction) as a contraindication. The medication is contraindicated for use in individuals with a known allergy to Dicycloverine hydrochloride or to any of the other non-active ingredients (excipients) used in the formulation.


Q: What happens if a person takes too much Loverin?

Official information on overdose symptoms typically includes headache, blurred vision, dizziness, dry mouth, and effects on the Central Nervous System (CNS), such as agitation or confusion. In an overdose situation, treatment is generally focused on managing the symptoms.


Q: What is the purpose of the 'inactive ingredients' listed in Loverin?

Inactive ingredients, also called excipients, are substances used to create the final form of the medicine (tablet, capsule, or liquid). Their purpose is to provide structure, bulk, aid in stability, ensure correct dissolution, or improve taste, and they do not contribute to the drug's intended medicinal effects.


Q: What does 'contraindicated' mean in the context of Loverin?

Contraindicated is a term used in official documents meaning that a drug must not be used for an individual with a specific condition. For Loverin, this includes certain diseases like glaucoma, myasthenia gravis, obstructive uropathy, obstructive disease of the GI tract, and severe ulcerative colitis.


Q: Will Loverin interfere with birth control pills?

Official drug interaction summaries do not typically highlight oral contraceptives as a specific interaction. However, because Loverin is an anticholinergic drug, it could potentially affect the rate at which various oral medicines, including birth control, are absorbed in the digestive tract.


Q: Does Loverin interact with herbal supplements like St. John's Wort?

Official product labeling does not usually provide a complete list of interactions with all herbal and dietary supplements, including St. John's Wort. Official patient information notes the importance of ensuring the prescribing professional is aware of all supplements being taken.


Q: Is there a generic version of Loverin available?

Yes, Dicycloverine is the name of the active ingredient and is widely available as a generic medicine. The generic form contains the same active drug and meets the same standards as the brand-name product.


Q: What are the official clinical trial results for Loverin?

Clinical trials have indicated that the maximum daily dosage of Dicycloverine was superior to a placebo in reducing global symptoms related to Irritable Bowel Syndrome (IBS). However, regulatory reviews have also noted that the overall body of evidence supporting its effectiveness is limited.


Q: Is Loverin used in emergency medical situations?

The injectable (intramuscular or IM) formulation is intended only for temporary, short-term use, often for individuals who cannot take the medication orally. Official use guidelines restrict this injectable use to one or two days maximum before transitioning to oral therapy.


Q: Are there different strengths or formulations of Loverin available?

Yes, official documents describe several forms. Dicycloverine is available as oral tablets (commonly 10 mg and 20 mg), an oral solution (10 mg/5 mL), and an injectable solution for intramuscular use.


Q: Can I stop taking Loverin suddenly, or do I need to reduce the amount slowly?

Official documents related to discontinuation do not explicitly include instructions for tapering the dose. However, they indicate that if the medication is discontinued, previous symptoms such as cramps or pain may return.


Q: Is it common to feel tired when first starting Loverin?

Yes, official labeling lists tiredness, also described as weakness or drowsiness, as a reported side effect of Dicycloverine. This is classified as a common adverse reaction due to the drug's effects on the central nervous system.


Q: Where can I find the official regulatory information about Loverin?

Official regulatory and prescribing information can be found on government websites. In the U.S., this includes the National Institutes of Health (NIH) DailyMed service and the Food and Drug Administration (FDA) website.


Q: Can I take vitamins or minerals while on a course of Loverin?

Specific interactions between Dicycloverine and vitamins or minerals are generally not detailed in regulatory documents. It is important to remember that this type of drug may affect the absorption rate of various other medicines or supplements taken orally.


Q: What should I tell a new doctor about my Loverin use?

The official patient information includes a recommendation to disclose all medications, supplements, and vitamins being taken, as well as any existing health conditions, to a healthcare professional.


Q: What is the shelf life of Loverin?

The official shelf life is specified on the medication's packaging and is based on stability studies. Typically, this is around 5 years from the date of manufacture when the product is stored according to the specified temperature and humidity conditions.


Q: Can Loverin cause problems with sleep?

Yes, official labeling lists insomnia (difficulty falling or staying asleep) as a reported side effect. This is related to the medication's effects on the Central Nervous System (CNS).


Q: Is the research evidence for Loverin considered strong or limited?

Regulatory reviews have concluded that while the medicine is effective for its stated use, the supporting evidence is considered limited. Some analyses cite a 'very low' quality of evidence based on the number of controlled clinical studies available.


Q: Are there any specific diseases that make a person ineligible for Loverin?

Yes, official labeling lists several diseases that are contraindications (reasons the drug cannot be used). These include glaucoma, myasthenia gravis, obstructive uropathy, obstructive disease of the GI tract, and severe ulcerative colitis.


Q: Does taking Loverin mean I can stop other therapies for my condition?

Dicycloverine is designated as an adjunctive or supplementary therapy for its condition of use. Official information implies that it is used in addition to other measures, not necessarily as a replacement.

How should Loverin be stored and disposed of?

Storage Requirements

Loverin (Dicycloverine) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C (86 F). The regulatory labeling mandates that the product must not be frozen and must be kept in its original, tightly closed container.

Protection and Child Safety

To maintain stability, the medication must be protected from light and excessive moisture. All forms of Loverin must be stored in a secured location, strictly out of the reach and sight of children and pets.

Disposal Instructions

Unused or expired product should be discarded following official guidelines, preferably through an authorized drug take-back program. If a take-back program is unavailable, the medicine must be mixed with an undesirable substance, sealed in a bag, and then placed in the household trash. Used needles or syringes from the injectable form must be placed immediately in an FDA-cleared, puncture-resistant sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loverin found in:

A-Z Index: